AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Metformin for Cardioprotection During Vascular Endothelial Growth Factor Inhibitor Therapy: A Retrospective Cohort Study
By Haroun F, Dulal D, Wright J et al.
Background: Vascular endothelial growth factor inhibitors (VEGFi) are essential antineoplastics. However, their use is frequently limited by cardiovascular toxicities, including heart failure. Metformin exerts pleiotropic effects that may confer cardiovascular protection independent of its glucose-lowering effects. Research Question: This study aims to investigate whether metformin use is associated with a reduced risk of cancer therapy-related cardiac dysfunction (CTRCD) and all-cause mortality in patients undergoing cancer treatment with a VEGFi. Methods: A retrospective analysis was conducted using the TriNetX research network. We identified adult cancer patients who initiated VEGFi therapy between 2010 and 2024, with no prior diagnosis of heart failure, cardiomyopathy, or a left ventricular ejection fraction <50%. Patients were categorized by metformin use. Propensity score matching, incorporating demographics, comorbidities, and baseline cardiovascular medications, was completed to minimize confounding. After matching, all standardized mean differences were <0.1, indicating adequate covariate balance. The primary outcomes were CTRCD and all-cause mortality. Secondary outcomes included heart failure exacerbation and new-onset metastatic cancer. CTRCD was defined as a composite endpoint consisting of a new diagnosis of heart failure, cardiomyopathy, newly documented LVEF ≤40%, or initiation of loop diuretic therapy. Time-to-event outcomes were evaluated using Kaplan-Meier survival analysis and Cox proportional hazards models over a follow-up period of up to one year. Results: Our study included two matched cohorts of 15,769 patients each. During the follow-up period, patients using metformin had a significantly lower risk of CTRCD (17.2% vs. 17.8%; HR 0.94, 95% CI 0.89-0.99; p = 0.028) and all-cause mortality (19.8% vs. 23.0%; HR 0.83, 95% CI 0.79-0.87; p < 0.001). Metformin use was also associated with significant reductions in the risk of heart failure exacerbation (5.5% vs. 6.6%; HR 0.82, 95% CI 0.75-0.90; p < 0.001) and new-onset metastatic cancer (10.6% vs. 12.8%; HR 0.81, 95% CI 0.74-0.88; p < 0.001). Conclusions: This is the largest real-world, propensity-matched analysis demonstrating that in cancer patients treated with a VEGFi, metformin use at cancer therapy initiation is associated with a significantly lower incidence of CTRCD and a reduced risk of heart failure exacerbations. Notably, these cardioprotective associations did not appear to compromise antineoplastic efficacy as metformin use was associated with a marked reduction in all-cause mortality and new-onset metastatic disease. Therefore, metformin use may be a promising cardioprotective strategy in this patient population. Further prospective trials are warranted to evaluate the effects of metformin on cardiovascular and oncologic outcomes in combination with VEGFi.